CYTK News and Press, Cytokinetics Incorporated

Late Breaking Clinical Trial Presentations to Feature Additional Results from SEQUOIA-HCM Related to Patient-Reported Health Status, Cardiac Structure and Function and Biomarkers Analyses of Safety and Outcomes from FOREST-HCM Related to Withdrawal of Standard of Care Medications to b...

2024-06-20 20:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian parti...

2024-06-05 10:28:20 ET More on Cytokinetics Cytokinetics Decides To Go It Alone Cytokinetics CEO Blum says positioned to market heart drug aficamten by itself Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics drops after pricing p...

2024-06-04 10:30:05 ET B. Riley analyst issues BUY recommendation for CYTK on June 4, 2024 08:58AM ET. The previous analyst recommendation was Buy. CYTK was trading at $49.018 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in June: Jefferies Global Healthcare Conference: Robert I. Blum, President and Chi...

2024-05-29 14:45:14 ET Summary Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. ...

SOUTH SAN FRANCISCO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 9,803,922 shares of its common stock at a price to the public of $51.00 per share. The gro...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-24 14:48:52 ET Summary The stock of Cytokinetics, Incorporated plunged 17% in trading on Thursday, largely as the result of a somewhat botched capital raise announcement. The capital raise took a near-term buyout off the table in the short term and left many shareholders f...